US FDA declines to approve Novocure's lung cancer device
US FDA declines to approve Novocure's lung cancer device Nov 9 (Reuters) - Novocure NVCR.O said on Monday the US health regulator has declined to approve its device for patients whose lung cancer has spread to the brain.
The company had submitted an application seeking approval for Optune Mya — the device meant for adults with brain tumors from non-small cell lung cancer who have already had stereotactic radiation, a precise form of radiation treatment
The US Food and Drug Administration was unsure about how much clinical benefit the device could provide to patients, according to the company's release
The agency did not raise safety concerns, the cancer treatment device maker said
Novocure had reported in 2024 that a late-stage trial met its main goal of delaying brain tumor growth in lung cancer patients, but preliminary results for overall survival did not reach statistical significance
Optune Mya uses the company's tumor treating fields technology, which delivers electric fields designed to disrupt cancer cell growth
Novocure said it was reviewing the FDA's feedback and plans to meet with the agency to see whether there are any options that would support the approval of its application without requiring additional clinical studies
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shilpi Majumdar)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on NovoCure
See all newsBrief: Novocure’s PANOVA-3 Quality of Life, Pain Data Published in JAMA Network Open
US FDA declines to approve Novocure's lung cancer device
Brief: Novocure Provides FDA Update on Optune Mya Approval Application for Lung Cancer Brain Metastases
NovoCure Limited reports results for the quarter ended September 30 - Earnings Summary
Switzerland's Novocure Q3 revenue rises 16%, beats estimates